Literature DB >> 7533215

High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

D Neri1, M Momo, T Prospero, G Winter.   

Abstract

We have developed a strategy for making antibody fragments with high binding affinities by harnessing the chelate effect. We create a bispecific antibody fragment (Chelating Recombinant Antibody or CRAb) that recognizes adjacent and non-overlapping epitopes of the target antigen, and is flexible enough to bind to both epitopes simultaneously. Here the strategy is illustrated with two antibodies that form complexes of known three-dimensional structure against different epitopes of lysozyme. Computer graphic modelling indicated that two single-chain antibody fragments (scFv) derived from antibodies D1.3 (Ka = 10(8) M-1) and mutant HyHEL-10 (Ka = 10(6) M-1) could be linked together on the surface of lysozyme by a flexible and hydrophilic polypeptide between the C terminus of one fragment and the N terminus of the other. The CRAb gene was assembled and the CRAb expressed by secretion from bacteria. The purified CRAb was shown to have a much higher affinity than either of the scFv fragments, as shown by competition ELISA (Kd > 10(9) M-1), bandshift on gels (Ka > 2 x 10(9) M-1) and fluorescence quench (Ka > 1.3 x 10(10) M-1).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533215     DOI: 10.1006/jmbi.1994.0091

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  24 in total

1.  Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone methylation.

Authors:  Takamitsu Hattori; Darson Lai; Irina S Dementieva; Sherwin P Montaño; Kohei Kurosawa; Yupeng Zheng; Louesa R Akin; Kalina M Świst-Rosowska; Adrian T Grzybowski; Akiko Koide; Krzysztof Krajewski; Brian D Strahl; Neil L Kelleher; Alexander J Ruthenburg; Shohei Koide
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

2.  Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains.

Authors:  Huan-Xiang Zhou
Journal:  Biophys J       Date:  2006-08-04       Impact factor: 4.033

3.  Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region.

Authors:  P C Keck; J S Huston
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

Review 4.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

5.  A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.

Authors:  Alessandra Villa; Valeria Lovato; Emil Bujak; Sarah Wulhfard; Nadine Pasche; Dario Neri
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 6.  Engineering recombinant antibodies for immunotherapy.

Authors:  D Neri; H Petrul; G Roncucci
Journal:  Cell Biophys       Date:  1995-08

7.  Efficient one-step direct labelling of recombinant antibodies with technetium-99m.

Authors:  M Liberatore; D Neri; G Neri; A Pini; A P Iurilli; F Ponzo; G Spampinato; F Padula; A Pala; A C Colella
Journal:  Eur J Nucl Med       Date:  1995-11

8.  "Peptabody": a new type of high avidity binding protein.

Authors:  A V Terskikh; J M Le Doussal; R Crameri; I Fisch; J P Mach; A V Kajava
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

9.  Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding.

Authors:  Nathan Scott; Omar Qazi; Michael J Wright; Neil F Fairweather; Mahendra P Deonarain
Journal:  Mol Immunol       Date:  2010-04-22       Impact factor: 4.407

10.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.